Nektar Therapeutics (NKTR)
74.96
+1.27
(+1.72%)
USD |
NASDAQ |
Aug 25, 16:00
74.90
-0.06
(-0.07%)
After-Hours: 19:59
Nektar Therapeutics Debt to Equity Ratio : 0.1505 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1505 |
| March 31, 2026 | 0.2489 |
| December 31, 2025 | 1.658 |
| September 30, 2025 | 1.964 |
| June 30, 2025 | -7.300 |
| March 31, 2025 | 13.59 |
| December 31, 2024 | 3.200 |
| September 30, 2024 | 4.216 |
| June 30, 2024 | 2.756 |
| March 31, 2024 | 1.830 |
| December 31, 2023 | 1.759 |
| September 30, 2023 | 1.537 |
| June 30, 2023 | 1.322 |
| March 31, 2023 | 1.135 |
| December 31, 2022 | 0.7036 |
| September 30, 2022 | 0.7284 |
| June 30, 2022 | 0.6894 |
| March 31, 2022 | 0.5393 |
| December 31, 2021 | 0.4287 |
| September 30, 2021 | 0.4095 |
| June 30, 2021 | 0.3718 |
| March 31, 2021 | 0.3474 |
| December 31, 2020 | 0.2974 |
| September 30, 2020 | 0.1885 |
| June 30, 2020 | 0.1792 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.3712 |
| December 31, 2019 | 0.3208 |
| September 30, 2019 | 0.3198 |
| June 30, 2019 | 0.2724 |
| March 31, 2019 | 0.2601 |
| December 31, 2018 | 0.1797 |
| September 30, 2018 | 0.1854 |
| June 30, 2018 | 0.18 |
| March 31, 2018 | 5.808 |
| December 31, 2017 | 3.655 |
| September 30, 2017 | 4.113 |
| June 30, 2017 | 103.37 |
| March 31, 2017 | 7.874 |
| December 31, 2016 | 3.800 |
| September 30, 2016 | -5.253 |
| June 30, 2016 | -9.185 |
| March 31, 2016 | -1326.79 |
| December 31, 2015 | 53.87 |
| September 30, 2015 | 6.488 |
| June 30, 2015 | 7.280 |
| March 31, 2015 | 3.316 |
| December 31, 2014 | 6.420 |
| September 30, 2014 | 5.312 |
| June 30, 2014 | -7.140 |
| March 31, 2014 | -25.81 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Elite Pharmaceuticals, Inc. | 0.0532 |
| Daré Bioscience, Inc. | -12.08 |
| Aclaris Therapeutics, Inc. | 0.0149 |
| Eton Pharmaceuticals, Inc. | 0.6273 |
| Journey Medical Corp. | 0.7953 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.095B |
| Total Liabilities (Quarterly) | 192.01M |
| Shareholders Equity (Quarterly) | 903.12M |
| Current Ratio | 10.42 |
| Net Debt Paydown Yield | 0.43% |